Ensuring Patient Access To Critical Breakthrough Products Act Of 2023

AI Summary

The "Ensuring Patient Access to Critical Breakthrough Products Act of 2023" aims to improve patient access to innovative medical products by streamlining the approval process for breakthrough therapies. The bill proposes provisions to expedite the review and approval of breakthrough products by the Food and Drug Administration (FDA), ensuring timely access for patients in need. This legislation seeks to enhance collaboration between stakeholders, facilitate efficient regulatory pathways, and promote innovation in the healthcare industry. If enacted, this bill could lead to faster availability of cutting-edge treatments and better outcomes for patients with serious or life-threatening conditions.

• 2023-03-22: Introduced in House

• 2023-03-22: Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

• 2023-03-31: Referred to the Subcommittee on Health.

• 2023-11-15: Subcommittee Consideration and Mark-up Session Held

• 2023-11-15: Forwarded by Subcommittee to Full Committee by the Yeas and Nays: 21 - 6.

• 2024-06-27: Committee Consideration and Mark-up Session Held

• 2024-06-27: Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 36 - 5.